Sutro Biopharma gains; Truist raises PT on co

Sutro Biopharma

13/01/2023 16:02

** Shares of Sutro Biopharma Inc  STRO.O  up 6.5% at $8.17 
    ** Brokerage Truist Securities raises PT on STRO to $25 from
$21 on prospects for its experimental ovarian cancer drug
STRO-002
    ** Recent data from an early-stage trial of the drug
delivered on many efficacy goals such as overall response rate
and progression free survival - Truist
    ** Though data showed STRO-002's durability below
ImmunoGen's  IMGN.O  already approved ovarian cancer therapy
Elahere, expect drug will be approvable if data from the trial
can be replicated in a pivotal study - brokerage
    ** Truist says it also expects "the pivotal data has
potential to improve"
    ** STRO has gained ~40% in past 6 months
 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))